Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.
Vlaar APJ, de Bruin S, Busch M, Timmermans SAMEG, van Zeggeren IE, Koning R, Ter Horst L, Bulle EB, van Baarle FEHP, van de Poll MCG, Kemper EM, van der Horst ICC, Schultz MJ, Horn J, Paulus F, Bos LD, Wiersinga WJ, Witzenrath M, Rueckinger S, Pilz K, Brouwer MC, Guo RF, Heunks L, van Paassen P, Riedemann NC, van de Beek D. Vlaar APJ, et al. Among authors: witzenrath m. Lancet Rheumatol. 2020 Dec;2(12):e764-e773. doi: 10.1016/S2665-9913(20)30341-6. Epub 2020 Sep 28. Lancet Rheumatol. 2020. PMID: 33015643 Free PMC article.
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Vlaar APJ, Witzenrath M, van Paassen P, Heunks LMA, Mourvillier B, de Bruin S, Lim EHT, Brouwer MC, Tuinman PR, Saraiva JFK, Marx G, Lobo SM, Boldo R, Simon-Campos JA, Cornet AD, Grebenyuk A, Engelbrecht JM, Mukansi M, Jorens PG, Zerbib R, Rückinger S, Pilz K, Guo R, van de Beek D, Riedemann NC; PANAMO study group. Vlaar APJ, et al. Among authors: witzenrath m. Lancet Respir Med. 2022 Dec;10(12):1137-1146. doi: 10.1016/S2213-2600(22)00297-1. Epub 2022 Sep 7. Lancet Respir Med. 2022. PMID: 36087611 Free PMC article. Clinical Trial.
Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial.
Kurth F, Helbig ET, Lippert LJ, Thibeault C, Barbone G, Eckart MA, Kluge M, Puengel T, Demir M, Röhle R, Keller T, Ruwwe-Glösenkamp C, Witzenrath M, Suttorp N, von Kalle C, Sander LE, Jochum C, Tacke F. Kurth F, et al. Among authors: witzenrath m. J Glob Antimicrob Resist. 2023 Mar;32:44-47. doi: 10.1016/j.jgar.2022.12.004. Epub 2022 Dec 23. J Glob Antimicrob Resist. 2023. PMID: 36572146 Free PMC article. Clinical Trial.
A proteomic survival predictor for COVID-19 patients in intensive care.
Demichev V, Tober-Lau P, Nazarenko T, Lemke O, Kaur Aulakh S, Whitwell HJ, Röhl A, Freiwald A, Mittermaier M, Szyrwiel L, Ludwig D, Correia-Melo C, Lippert LJ, Helbig ET, Stubbemann P, Olk N, Thibeault C, Grüning NM, Blyuss O, Vernardis S, White M, Messner CB, Joannidis M, Sonnweber T, Klein SJ, Pizzini A, Wohlfarter Y, Sahanic S, Hilbe R, Schaefer B, Wagner S, Machleidt F, Garcia C, Ruwwe-Glösenkamp C, Lingscheid T, Bosquillon de Jarcy L, Stegemann MS, Pfeiffer M, Jürgens L, Denker S, Zickler D, Spies C, Edel A, Müller NB, Enghard P, Zelezniak A, Bellmann-Weiler R, Weiss G, Campbell A, Hayward C, Porteous DJ, Marioni RE, Uhrig A, Zoller H, Löffler-Ragg J, Keller MA, Tancevski I, Timms JF, Zaikin A, Hippenstiel S, Ramharter M, Müller-Redetzky H, Witzenrath M, Suttorp N, Lilley K, Mülleder M, Sander LE; PA-COVID-19 Study group; Kurth F, Ralser M. Demichev V, et al. Among authors: witzenrath m. PLOS Digit Health. 2022 Jan 18;1(1):e0000007. doi: 10.1371/journal.pdig.0000007. eCollection 2022 Jan. PLOS Digit Health. 2022. PMID: 36812516 Free PMC article.
Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19.
Thibeault C, Bardtke L, Vanshylla K, di Cristanziano V, Eberhardt KA, Stubbemann P, Hillus D, Tober-Lau P, Mukherjee P, Münn F, Lippert LJ, Helbig ET, Lingscheid T, Steinbeis F, Mittermaier M, Witzenrath M, Zoller T; Pa-COVID study group; Klein F, Sander LE, Kurth F. Thibeault C, et al. Among authors: witzenrath m. JCI Insight. 2023 Apr 24;8(8):e166711. doi: 10.1172/jci.insight.166711. JCI Insight. 2023. PMID: 36881474 Free PMC article.
Neutralizing Complement C5a Protects Mice with Pneumococcal Pulmonary Sepsis.
Müller-Redetzky H, Kellermann U, Wienhold SM, Gutbier B, Lienau J, Hellwig K, Reppe K, Letsiou E, Tschernig T, Scholz M, Ahnert P, Maasch C, Hoehlig K, Klussmann S, Vater A, Firsching TC, Hoppe J, Suttorp N, Witzenrath M. Müller-Redetzky H, et al. Among authors: witzenrath m. Anesthesiology. 2020 Apr;132(4):795-807. doi: 10.1097/ALN.0000000000003149. Anesthesiology. 2020. PMID: 32101978 Free article.
Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study.
Thibeault C, Mühlemann B, Helbig ET, Mittermaier M, Lingscheid T, Tober-Lau P, Meyer-Arndt LA, Meiners L, Stubbemann P, Haenel SS, Bosquillon de Jarcy L, Lippert L, Pfeiffer M, Stegemann MS, Roehle R, Wiebach J, Hippenstiel S, Zoller T, Müller-Redetzky H, Uhrig A, Balzer F, von Kalle C, Suttorp N, Jones TC, Drosten C, Witzenrath M, Sander LE; Pa-COVID Study Group; Corman VM, Kurth F. Thibeault C, et al. Among authors: witzenrath m. Infection. 2021 Aug;49(4):703-714. doi: 10.1007/s15010-021-01594-w. Epub 2021 Apr 22. Infection. 2021. PMID: 33890243 Free PMC article.
Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study.
Mühlemann B, Thibeault C, Hillus D, Helbig ET, Lippert LJ, Tober-Lau P, Schwarz T, Müller MA; Pa-COVID-19 collaborative study group; Witzenrath M, Suttorp N, Sander LE, Drosten C, Jones TC, Corman VM, Kurth F. Mühlemann B, et al. Among authors: witzenrath m. Clin Microbiol Infect. 2021 Oct;27(10):1520.e7-1520.e10. doi: 10.1016/j.cmi.2021.06.008. Epub 2021 Jun 15. Clin Microbiol Infect. 2021. PMID: 34139335 Free PMC article.
Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01.
Weiner J, Suwalski P, Holtgrewe M, Rakitko A, Thibeault C, Müller M, Patriki D, Quedenau C, Krüger U, Ilinsky V, Popov I, Balnis J, Jaitovich A, Helbig ET, Lippert LJ, Stubbemann P, Real LM, Macías J, Pineda JA, Fernandez-Fuertes M, Wang X, Karadeniz Z, Saccomanno J, Doehn JM, Hübner RH, Hinzmann B, Salvo M, Blueher A, Siemann S, Jurisic S, Beer JH, Rutishauser J, Wiggli B, Schmid H, Danninger K, Binder R, Corman VM, Mühlemann B, Arjun Arkal R, Fragiadakis GK, Mick E, Comet C, Calfee CS, Erle DJ, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Langelier CR, Venkataramani U, García F, Zyla J, Drosten C, Alice B, Jones TC, Suttorp N, Witzenrath M, Hippenstiel S, Zemojtel T, Skurk C, Poller W, Borodina T, Pa-Covid SG, Ripke S, Sander LE, Beule D, Landmesser U, Guettouche T, Kurth F, Heidecker B. Weiner J, et al. Among authors: witzenrath m. EClinicalMedicine. 2021 Oct;40:101099. doi: 10.1016/j.eclinm.2021.101099. Epub 2021 Sep 2. EClinicalMedicine. 2021. PMID: 34490415 Free PMC article.
Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study.
Lingscheid T, Lippert LJ, Hillus D, Kruis T, Thibeault C, Helbig ET, Tober-Lau P, Pfäfflin F, Müller-Redetzky H, Witzenrath M, Zoller T, Uhrig A, Opitz B, Suttorp N, Kramer TS, Sander LE, Stegemann MS, Kurth F. Lingscheid T, et al. Among authors: witzenrath m. Infection. 2022 Dec;50(6):1441-1452. doi: 10.1007/s15010-022-01796-w. Epub 2022 Apr 14. Infection. 2022. PMID: 35420370 Free PMC article.
266 results